Supplementary Tables

Table S1. Respiratory medication used by GOLD stage

Medication	All patients (n = 4,484)	COPD severity			
		1 (n = 794)	2 (n = 1,922)	3 (n = 1,162)	4 (n = 606)
No respiratory medication (%)	34.4	75.3	41.9	11.2	1.7
SABA (%)	52.1	17.8	45.0	70.3	84.8
ICS/LABA (%)	36.0	9.1	28.7	52.1	63.2
LAMA (%)	33.5	6.4	24.1	50.5	66.2
SABA/SAMA (%)	17.0	6.2	13.3	22.4	32.8
ICS (%)	10.6	4.2	8.3	13.9	20.1
SAMA (%)	8.9	1.3	6.9	13.0	17.3
LABA (%)	7.2	1.4	4.9	10.2	16.5
Oral CS (%)	4.8	0.8	2.7	6.7	13.4
Theophylline (%)	3.8	0.4	1.8	4.8	12.9

Patients may have taking more than one medication.
ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LAMA, long-acting muscarinic antagonist; OR, odds ratio; SABA, short-acting beta2-agonist; SAMA, short-acting muscarinic antagonist.

Table S2. Number of medications per patient by GOLD stage

Number of medication	All patients (n=4,484)	COPD severity			
		1 (n=794)	2 (n=1,922)	3 (n=1,162)	4 (n=606)
0	34.4	75.3	41.9	11.2	1.7
1	13.0	9.9	16.0	14.2	5.3
2	17.5	8.8	18.6	22.5	15.8
3	21.8	4.5	15.4	33.5	42.6
4	8.6	1.0	5.7	12.8	19.6
5	2.8	0.3	1.6	3.4	8.7
6	1.1	0	0.4	1.3	4.1
7	0.6	0.1	0.3	0.9	1.7
8	0.2	0	0.2	0.2	0.5
9	0.0	0	0	0.1	0